TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21126595
Drug: Transplanted CD34(+)
Normalized name: CD34+ Cells
DrugBank: Autologous peripheral blood-derived CD34+ cells (DB16367)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transplanted CD34(+) cell dose levels: 2-4 × 10(6) cells/kg, 4-6 × 10(6) cells/kg, >6 × 10(6) cells/kg
Study: 17668526
Drug: Clindamycin phosphate
Normalized name: Clindamycin Phosphate
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clindamycin phosphate 1.2% and tretinoin 0.025% gel (CLIN/RA gel)
Study: 15479494
Drug: Paclitaxel 100
Normalized name: paclitaxel 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel 100 mg/m2 plus estramustine 280 mg orally 3 times a day
Study: 15479494
Drug: Paclitaxel 100
Normalized name: paclitaxel 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel 100 mg/m2 alone
Study: 9547441
Drug: Nebivolol 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol 5.0 mg
Study: 9825177
Drug: d-nebivolol 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-nebivolol 2.5 mg
Study: 9825177
Drug: l-nebivolol 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-nebivolol 2.5 mg
Study: 9825177
Drug: Racemic nebivolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Racemic nebivolol (2.5, 5.0, and 10.0 mg)
Study: 8074059
Drug: Nicotine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine (15 micrograms/kg) combined with caffeine (5 mg/kg) during activity
Study: 8074059
Drug: Caffeine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (5 mg/kg) during activity
Study: 2510845
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (20 mg elemental zinc daily)
Study: 2510845
Drug: Placebo (capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (capsule identical in appearance and taste with inert substances)
Study: 29231502
Drug: Auricular sticking
Normalized name: Zit Stick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auricular sticking therapy with semen vaccariae, applied every three days for 2 weeks, combined with western medication.
Study: 29231502
Drug: Auricular pseudo-press
Normalized name: garden cress sprout extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auricular pseudo-press therapy, applied every three days for 2 weeks, combined with western medication.
Study: 11325322
Drug: Tricyclic antidepressant
Normalized name: Tricyclic antidepressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tricyclic antidepressant medication (amitriptyline hydrochloride, up to 100 mg/d, or nortriptyline hydrochloride, up to 75 mg/d)
Study: 11325322
Drug: Stress management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stress management therapy (3 sessions and 2 telephone contacts) plus placebo
Study: 11325322
Drug: Stress management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stress management therapy plus antidepressant medication
Study: 9513669
Drug: Intravenous tenoxicam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tenoxicam 40 mg
Study: 1884268
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of peroperative and postoperative transfusion (Group III)
Study: 6411615
Drug: Intravenous fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fat tolerance test
Study: 6411615
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral nutrition with fat dosage of 2.5 g/kg X d‐1
Study: 31818053
Drug: Sports medicine
Normalized name: Mueller Sports Medicine Compression Glove
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sports medicine physician (SMP)
Study: 28323797
Drug: Local vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local vancomycin powder (up to a maximum dose of 1000 mg, placed immediately before wound closure)
Study: 27475691
Drug: Fentanyl Transdermal
Normalized name: Fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl Transdermal System (FTS)
Study: 27475691
Drug: Control (placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (placebo patch and analgesic)
Study: 21037490
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acids (eicosapentaenoic acid and docosahexaenoic acid, 2 g/d)
Study: 20110013
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of rebamipide 100 mg
Study: 20110013
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of rebamipide 100 mg
Study: 11234938
Drug: Insulin-dependent diabetics
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-dependent diabetics
Study: 11234938
Drug: Non-insulin-dependent diabetics
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-insulin-dependent diabetics
Study: 10225575
Drug: Ciprofloxacin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (100 mg bd for 3 days)
Study: 10225575
Drug: Co-trimoxazole (160/800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-trimoxazole (160/800 mg bd for 7 days)
Study: 10225575
Drug: Nitrofurantoin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrofurantoin (100 mg bd for 7 days)
Study: 8059818
Drug: Monophasic combination
Normalized name: Monobasic Potassium Phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monophasic combination of 30 micrograms ethinyl estradiol and 75 micrograms gestodene (treatment group, n = 12)
Study: 2741619
Drug: Continuous glucose-saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous glucose-saline infusion
Study: 2741619
Drug: 5-hour glucose
Normalized name: Glucose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-hour glucose infusion
Study: 2741619
Drug: Standardized intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized intravenous fluids
Study: 26799528
Drug: Bone-level implants
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone-level implants with mucosal thickness ≤2 mm (Group A, MC)
Study: 26799528
Drug: Bone-level implants
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone-level implants with mucosal thickness >2 mm (Group B, MC)
Study: 26799528
Drug: Tissue-level implants
Normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tissue-level implants with mucosal thickness ≤2 mm (Group A, LC)
Study: 26799528
Drug: Tissue-level implants
Normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tissue-level implants with mucosal thickness >2 mm (Group B, LC)
Study: 25727892
Drug: Alkalosis (ALK;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alkalosis (ALK; 0.3 g (kg body weight)(-1) sodium bicarbonate)
Study: 25727892
Drug: Placebo (PLA;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PLA; 0.3 g (kg body weight)(-1) calcium carbonate)
Study: 18293426
Drug: Androgen deprivation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen deprivation therapy (ADT) as part of local treatment
Study: 11261502
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg glatiramer acetate (GA)
Study: 8300824
Drug: Glutathione therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutathione therapy (600 mg i.m. injection every other day for 2 months)
Study: 8300824
Drug: Placebo (equal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (equal volume of a placebo preparation for 2 months)
Study: 3814032
Drug: Atropine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine (4 mg X 70 kg‐1 body weight)
Study: 3814032
Drug: 2-PAM chloride
Normalized name: 2-PAM chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-PAM chloride (up to 1200 mg X 70 kg‐1 body weight)
Study: 27938540
Drug: H2∶O2 mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: H2∶O2 mixture (66.67%∶33.33%) inhalation for 1 hour per day for 30 days
Study: 27938540
Drug: N2∶O2 mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: N2∶O2 mixture (66.67%∶33.33%) inhalation for 1 hour per day for 30 days
Study: 24955451
Drug: 2-L polyethylene
Normalized name: Iron(2+) L-ascorbate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-L polyethylene glycol + ascorbic acid (PEG + Asc)
Study: 24955451
Drug: 4-L polyethylene
Normalized name: polyethylene glycol 3350
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-L polyethylene glycol (4-L PEG)
Study: 18436114
Drug: Darapladib 40
Normalized name: Darapladib
DrugBank: Darapladib (DB06311)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darapladib 40 mg
Study: 26465780
Drug: Darapladib 160
Normalized name: Darapladib
DrugBank: Darapladib (DB06311)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darapladib 160 mg
Study: 16573804
Drug: Eudragit-L-coated mesalazine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eudragit-L-coated mesalazine tablets
Study: 16573804
Drug: Ethylcellulose-coated mesalazine
Normalized name: Ethylcellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethylcellulose-coated mesalazine tablets
Study: 12679312
Drug: Dextromethorphan 60
Normalized name: DEXTROMETHORPHAN 60MG/GG 1200MG SA TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextromethorphan 60 mg BID
Study: 12679312
Drug: Dextromethorphan 90
Normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dextromethorphan 90 mg BID
Study: 12679312
Drug: Dextromethorphan 60
Normalized name: DEXTROMETHORPHAN 60MG/GG 1200MG SA TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextromethorphan 60 mg thrice daily
Study: 12679312
Drug: Dextromethorphan 90
Normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dextromethorphan 90 mg thrice daily
Study: 12679312
Drug: Dextromethorphan 120
Normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dextromethorphan 120 to 270 mg/day
Study: 9013088
Drug: E2/NETA (continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2/NETA (continuous oral 17 beta‐oestradiol 2 mg day‐1 and norethisterone acetate 1 mg day‐1)
Study: 9013088
Drug: E2/MPA (transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2/MPA (transdermal 17 beta‐oestradiol 50 micrograms day‐1 with oral cyclic medroxyprogesterone acetate 10 mg day‐1 on days 17-28)
Study: 1524955
Drug: Bestatin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bestatin (30 mg orally daily for three months after molar deliveries)
Study: 1524955
Drug: Bestatin non-administered
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bestatin non-administered group
Study: 21234550
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch (NIC)
Study: 23689969
Drug: Neydharting mud-pack
Normalized name: aminophylline / ephedrine hydrochloride / guaifenesin / phenobarbital Oral Tablet [Mudrane GG]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neydharting mud-pack therapy
Study: 18201563
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg pravastatin/day
Study: 8554936
Drug: (S)-flurbiprofen (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: (S)-flurbiprofen (50 mg)
Study: 8554936
Drug: (R)-flurbiprofen (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: (R)-flurbiprofen (50 mg)
Study: 8554936
Drug: (R)-flurbiprofen (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: (R)-flurbiprofen (100 mg)
Study: 2111665
Drug: Heparin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin therapy (5,000 IU)
Study: 31092252
Drug: Elements virtual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elements virtual rehabilitation (three weekly 30-40 min sessions for four weeks) combined with treatment as usual
Study: 23392747
Drug: HCl (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCl (0.1 N) infusion
Study: 11098966
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral nutrition enriched with arginine and glutamate (GlnP+ group)
Study: 11098966
Drug: Conventional total
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional total parenteral nutrition (control group)
Study: 9203170
Drug: Citicoline 1000
Normalized name: citicoline 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citicoline 1000 mg/day
Study: 9203170
Drug: Citicoline 500
Normalized name: citicoline 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citicoline 500 mg/day
Study: 9203170
Drug: Citicoline 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citicoline 300 mg/day + Nimodipine 90 mg/day
Study: 8315428
Drug: PCNU 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCNU 100 mg/m2 every 7 weeks for 1 year and every 10 weeks for the second year
Study: 8315428
Drug: BCNU 200
Normalized name: Carmustine
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BCNU 200 mg/m2 every 7 weeks for 1 year and every 10 weeks for the second year
Study: 29361312
Drug: Intravenous analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous analgesia (IV) with fentanyl, metamizole, dexketoprofen, ondansetron, and postoperative perfusion of metamizole 4%, tramadol 0.2%, ondansetron 0.08% 2ml·h‐1; PCA bolus 2mL/20min for 24 hours
Study: 27219522
Drug: DE‐EBRT with
Approvals — FDA: no, EMA: no, PMDA: no
Description: DE‐EBRT with bicalutamide 150 mg once daily for 5 months
Study: 27219522
Drug: DE‐EBRT without
Approvals — FDA: no, EMA: no, PMDA: no
Description: DE‐EBRT without hormone therapy
Study: 27219522
Drug: Dose escalation
Normalized name: PALFORZIA Initial Dose Escalation KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose escalation to >75.6 Gy
Study: 25044219
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral 600 mg dose of linezolid (LZD)
Study: 25044219
Drug: Linezolid (LZD)
Normalized name: Linezolid
DrugBank: Linezolid (DB00601)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Linezolid (LZD) administration timing
Study: 22950484
Drug: Intranasal dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal dexmedetomidine 1 μg.kg(‐1) (Group 1)
Study: 22950484
Drug: Intranasal dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal dexmedetomidine 2 μg.kg(‐1) (Group 2)
Study: 8981710
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy with TPA
Study: 1985608
Drug: Lovastatin 80
Normalized name: fluvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin 80 mg daily
Study: 1985608
Drug: Lovastatin 20
Normalized name: lovastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin 20 mg daily
Study: 1985608
Drug: Lovastatin 40
Normalized name: lovastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin 40 mg daily
Study: 30773934
Drug: Intravitreal dexamethasone
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal dexamethasone implant (Ozurdex®)
Study: 23375114
Drug: Recovery Line
Normalized name: Chem-Star Recover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recovery Line plus Treatment-as-Usual (TAU)
Study: 21107305
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g mycophenolate mofetil (group A, n=75)
Study: 21107305
Drug: 1.440 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.440 g enteric-coated mycophenolate sodium (group B, n=75)
Study: 19008470
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid treatment for 6 weeks
Study: 19008470
Drug: Folic acid,
Normalized name: folic acid, combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Folic acid, vitamin B(12), and vitamin B(6) treatment for 3 months
Study: 16182104
Drug: Regular red
Normalized name: acid red 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular red wine (250 mL)
Study: 16182104
Drug: Dealcoholized red
Normalized name: acid red 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dealcoholized red wine (250 mL)
Study: 10674881
Drug: Anastrozole 1
Normalized name: anastrozole 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anastrozole 1 mg and Megestrol acetate
Study: 6345893
Drug: Dialyzer clearance
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialyzer clearance of urea (Kd, ml/min)
Study: 6345893
Drug: Protein intake
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein intake monitoring (PCR, g/day)
Study: 27668943
Drug: Full-dose (FD)
Normalized name: Rho(D) immune globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose (FD) anticonvulsants
Study: 27668943
Drug: Half-dose (HD)
Normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-dose (HD) anticonvulsants
Study: 27668943
Drug: Stop anticonvulsants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stop anticonvulsants
Study: 27098525
Drug: Insulin Glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin Glargine (IGlar)
Study: 23346907
Drug: Calcium hydroxide
Normalized name: Calcium Hydroxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium hydroxide indirect pulp treatment (CH‐IPT)
Study: 23346907
Drug: Antibiotic sterilization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic sterilization using a mixture of three antibiotics (3Mix‐MP)
Study: 23938229
Drug: Deep brain
Normalized name: pork brain preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep brain stimulation plus optimal drug therapy
Study: 18775043
Drug: Drug challenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug challenge ECGs (group B)
Study: 12067328
Drug: Interferon-beta 1a
Normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-beta 1a (6 MIU once weekly i.m.)
Study: 9498655
Drug: Trandolapril 0.5
Normalized name: trandolapril 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trandolapril 0.5 mg day(-1) (L)
Study: 2677240
Drug: Brofaromine 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brofaromine 150 mg/day
Study: 31847
Drug: Behavior therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavior therapy and imipramine hydrochloride
Study: 1002948
Drug: Behavior therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavior therapy and placebo
Study: 31847
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment regimens (including imipramine and placebo) in simple phobic patients
Study: 31484021
Drug: Lifestyle Redesign®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lifestyle Redesign® occupational therapy (LR-OT)
Study: 23898894
Drug: Liberal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liberal treatment group received one unit of packed red blood cells and as much blood as needed to maintain hemoglobin concentrations at greater than 10 g/dL; median two units of blood received.
Study: 23898894
Drug: Restrictive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive treatment group received transfusions if they developed symptoms of anemia or their hemoglobin fell below 8 g/dL; median zero units of blood received.
Study: 21704240
Drug: Dalcetrapib 900
Normalized name: Dalcetrapib
DrugBank: Dalcetrapib (DB12181)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalcetrapib 900 mg in fed state
Study: 21704240
Drug: Dalcetrapib 600
Normalized name: Dalcetrapib
DrugBank: Dalcetrapib (DB12181)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalcetrapib 600 mg after light morning meal
Study: 21704240
Drug: Dalcetrapib 600
Normalized name: Dalcetrapib
DrugBank: Dalcetrapib (DB12181)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalcetrapib 600 mg after light evening meal
Study: 21704240
Drug: Dalcetrapib 600
Normalized name: Dalcetrapib
DrugBank: Dalcetrapib (DB12181)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalcetrapib 600 mg after standard evening meal
Study: 21704240
Drug: Dalcetrapib 600
Normalized name: Dalcetrapib
DrugBank: Dalcetrapib (DB12181)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalcetrapib 600 mg after high-fat evening meal
Study: 16319918
Drug: Paroxetine 10
Normalized name: PARoxetine 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine 10 mg/day for 2 weeks, then 20 mg/day for 2 weeks, then 30 mg/day for 2 weeks
Study: 16319918
Drug: Paroxetine (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (various doses)
Study: 10459684
Drug: 0.125 mg
Normalized name: digoxin 0.125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125 mg of triazolam (TRZ)
Study: 7608255
Drug: Metformin administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin administration (850 mg, twice daily for 4 months)
Study: 358763
Drug: Bendroflumethiazide (BFT),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendroflumethiazide (BFT), 10 mg, given orally after fasting overnight
Study: 358763
Drug: Bendroflumethiazide (BFT),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendroflumethiazide (BFT), 10 mg, given orally together with a meal
Study: 18802184
Drug: Standard drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard drug counseling
Study: 18802184
Drug: Motivational interviewing/skills-building
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational interviewing/skills-building therapy
Study: 16007412
Drug: S21403 (mitiglinide)
Normalized name: mitiglinide
DrugBank: Mitiglinide (DB01252)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: S21403 (mitiglinide) 40 mg
Study: 12407036
Drug: Fixed multiple
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed multiple dose antagonist protocol starting on day 6 of stimulation (group 1)
Study: 12407036
Drug: Individualized protocol
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized protocol with the time of antagonist start according to follicle size (14 mm, group 2)
Study: 12407036
Drug: Individualized single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized single dose protocol (group 3)
Study: 9802369
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (200 microg twice daily)